Alderley Park, 04 July 2023 – Blueberry Therapeutics is pleased to announce the completion of our European Phase 2b trial of BB2603 (BBTAF202). This trial is assessing the efficacy and safety of different doses of BB2603, a new topical anti-fungal spray formulation, in subjects with fungal nail infection (onychomycosis). The last subject entered has attended their last visit for the final Week 52 endpoint. We now turn our attention to preparing for the trial results. We would like to express our gratitude to all sites and participants for their continued involvement through this year-long trial period.
